A warning against GLP-1 weight loss 'obsession' Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 17 January, 2025

Corval is a cutting-edge technology solution that enables teams to quickly create a multi-year roadmap with a companion budget and resource plan through launch. sponsored by Corval

spotlight In Focus Broad Institute paper offers potential new framework for treating Huntington’s disease

news AstraZeneca wins BTK race to market in first-line mantle cell lymphoma After three-month delay, Amgen’s Lumakras clinches FDA green light in colorectal cancer Peer Review Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down Roche's cardiometabolic chief warns against weight loss 'obsession' with GLP-1s

Jan 29 12:00pm ET What’s on the horizon? The next era of alzheimer's treatments and diagnostics sponsored by Alzheimer's Drug Discovery Foundation Feb 04 12:00pm ET New data: Optimizing breast cancer care and drug development with molecular residual disease testing sponsored by Natera

Endpoints Pharma EMA in 2024 recommended highest number of drug approvals in 15 years Departing FDA commissioner: 'We're losing the battle on misinformation' HHS blasts Boehringer's drug price case, reveals new details on Jardiance talks Novartis enters fight against HHS for denying its 340B rebate model

in case you missed it 1. In first earnings since top exec’s murder, UnitedHealth Group diverts blame for healthcare frustrations 2. Bioregnum A mixed year for deals and dollars left biotech execs hungry for a better 2025 3. FDA rejects Atara's cell therapy for rare transplant complication, stock craters 4. Eli Lilly's Omvoh earns FDA approval for Crohn's disease 5. News Briefing Boehringer's schizophrenia asset fails Phase 3; GSK buys organoid biotech 6. Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus 7. Snake Antivenoms, Computed Science

Director Oligonucleotide R&D